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Maturity-onset diabetes of the young type 3 (MODY-3) is
a non-ketotic form of diabetes mellitus with an autosomic
dominant inheritance characterized by early onset (, 25 y)
and a severe impairment in insulin secretion.1 This disease
is caused by heterozygous germline mutations of the TCF1
gene. The product encoded by this gene is the hepatocyte
nuclear factor 1 alpha (HNF-1a – accession number NP_
000536) transcription factor, which has important physiolo-
gic roles in organs such as the pancreas, liver and kidneys.
Hepatocellular adenomas are benign neoplasms that
usually develop as a solitary nodule and are associated
with oral contraceptive use in 90% of cases. On the other
hand, liver adenomatosis (LA) is characterized by the
presence of multiple nodules (usually more than 5) and is
considered to be a distinct disease, due to the higher
prevalence in male sex and the unclear association with
OCs.2 LA has been reported in sporadic and familial forms.
Although malignant transformation is rarely observed,
spontaneous rupture and life-threatening bleeding may
occur in large and subcapsular nodules.3 For this reason,
large nodules should be resected.
Since the 1970s, some reports observed the co-segregation
of familial autosomic-dominant diabetes mellitus and LA,
suggesting that a common genetic factor may be associated
with both conditions.4,5 Biallelic somatic TCF1 inactivation
has been observed in about 50% of hepatocellular adeno-
mas, suggesting that this gene act as a tumor suppressor in
liver.6 Recently, germline TCF1 mutations have been
described in five familial cases of LA. In four of these
families, a co-segregation of LA and diabetes could be
clearly established. Interestingly, in all of these cases, the
identified germline TCF1 mutations were nonsense or frame-
shift.6-8 In this report, we describe a MODY-3 patient with
LA associated to a TCF1 missense germline mutation.
Case Report
A 27 year-old female who had a two-year history of non-
insulin dependent diabetes mellitus (NIDDM) underwent
an abdominal ultrasonography for unrelated causes. Multi-
ple hepatic nodules and liver enlargement were observed
(Figure 1). The patient reported the use of oral contra-
ceptives for the last 5 years and had a positive family history
for diabetes mellitus. An abdominal CT-scan was performed
and multiple hypervascularized hepatic nodules were
observed, consistent with the diagnosis of LA. The largest
nodule (18 cm) was resected and histological analysis
revealed a liver adenoma.
Genetic studies
An informed consent was obtained from the patient prior
to DNA extraction. Genomic and tumoral DNAs were
extracted from peripheral blood and paraffin-embedded
tissues samples, respectively, according to standard proto-
cols. The coding sequence of the entire TCF1 gene was
amplified by PCR. The amplified fragments were examined
on 2% agarosis gel electrophoresis. The PCR products were
directly sequenced using the BigDye Terminator cycle
sequencing ready reaction kit (Applied Biosystems, Foster
City, CA), in an ABI–PRISM 310 automatic sequencer
(Perkin-Elmer corp), after a pretreatment with an enzimatic
combination of exonucleade I and shrimp alkalyne phos-
phatase (ExoSap-it – United States biochemical corp.,
Cleveland, OH).
RESULTS
A single nucleotide substitution (CGT.CTT) was identi-
fied in heterozygous state in exon 4. This mutation encodes
an arginine for leucine substitution in codon 263 (R263L -
accession number NP_000536). Sequence analysis of tumo-
ral DNA identified a second (somatic) mutation of TCF1 –
the insertion of a cytosine residue in the polycytosine tract
of exon 4, causing a frameshift (P291fsInC).
DISCUSSION
In this paper, we report a rare association of MODY-3 and
LA. Although co-segregation of LA and autossomic-domi-
nant diabetes mellitus has been known since the 1970s,4
only in recent years this phenotype was associated to TCF1
germline mutations.6 To date, only five unrelated families
with LA and TCF1 germline mutations have been reported
so far,6-8 in spite of MODY-3 being a relatively common
genetic disease (, 1% of NIDDM).9 In most of familial cases,
the diagnosis of LA was established on index cases after an
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acute hemorrhagic complication. In the majority of affected
family members, the disease was mild and the diagnosis
was established after ultrasound screening. Since large-scale
imaging studies to evaluate the presence of LA in asympto-
matic MODY-3 patients are not available, it is speculated
that the prevalence of this condition may be underesti-
mated.
In spite of the fact that the majority of MODY-3 patients
are carriers of germline missense mutations,9 only nonsense or
frameshift mutations have been identified in the familial
cases of LA.6-8 Presumably, a severe impairment of the
HNF-1a function is required for the development of LA. The
germline mutation identified in our case (R263L) has been
recently described in a Korean MODY-3 family. Functional
analysis demonstrated that this mutation causes a signifi-
cant impairment of the HNF-1a function.10 We identified a
second (somatic) TCF1 mutation (P291fsInC) in the tumor
tissue. Interestingly, P291fsInC was identified as the first-hit
(germinative) mutation in two of the five described families.
Our findings are in accordance with previous reports, in
which the development of liver adenomas is associated to
the inactivation of both TCF1 alleles, either by allelic losses
at chromosome 12q or by double mutational events.6,8
Although OCs are known to be a classical risk factor for
the development of isolated liver adenomas (up to 90% of
such tumor are associated to OCs use), it is not clear if it
have a direct causal role in LA.2 Recent data suggest that at
least it may worsen the disease.5 For this reason, we suggest
that the use of OCs in MODY-3 patients should be
monitored with care. In conclusion, this is the first report
of LA associated to a missense TCF1 mutation. The impor-
tance of molecular diagnosis of MODY patients is rein-
forced, and MODY-3 patients should be screened for LA.
Also, the use of OCs in MODY-3 patients should be
carefully monitored. Alternative forms of contraception
should be considered.
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Figure 1 - Contrast-enhanced CT-scan showing multiple hypervas-
cularized hepatic nodules, consistent with the diagnosis of LA.
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